Victor Peralta1, Manuel J Cuesta. 1. Psychiatric Unit, Virgen del Camino Hospital, Pamplona, Spain. victor.peralta.martin@cfnavarra.es
Abstract
OBJECTIVE: To examine the effect of antipsychotic medication on neuromotor abnormalities in a sample of psychotic patients never exposed to antipsychotic drugs. METHOD: One hundred psychotic patients were assessed (from January 1998 to December 2002) using DSM-IV criteria for parkinsonism, dyskinesia, akathisia, catatonia, and dystonia at baseline and after 4 weeks of treatment with haloperidol (n = 23), risperidone (n = 52), or olanzapine (n = 25). We examined change scores in neuromotor ratings over the treatment period across treatment groups and rates of drug-responsive and drug-emergent neuromotor syndromes in patients with and without preexisting neuromotor abnormalities. RESULTS: Overall time effects revealed a worsening of parkinsonism (P = .002) and akathisia (P = .002) ratings and an improvement of dyskinesia (P = .001) and catatonia (P < .001) ratings. Main treatment effects revealed that patients taking haloperidol had a significant mean increase in akathisia scores compared with those of patients taking risperidone (P = .002) or olanzapine (P < .001). A significantly greater percentage of olanzapine-treated patients experienced remission of preexisting parkinsonism than did the other treatment groups (P = .047). Patients without preexisting motor abnormalities were more likely to experience drug-emergent parkinsonism if they were treated with haloperidol or risperidone than with olanzapine (P = .001) and were more likely to experience drug-emergent dystonia (P = .014) and akathisia (P = .013) if they were treated with haloperidol than with risperidone or olanzapine. CONCLUSIONS: The relationship between antipsychotic medication and neurologic abnormalities is more complex than previously acknowledged since antipsychotic drugs may both improve preexisting abnormalities and cause "de novo" neurologic syndromes. Overall, olanzapine has a more favorable neuromotor profile than risperidone, which in turn has a more favorable profile than haloperidol.
OBJECTIVE: To examine the effect of antipsychotic medication on neuromotor abnormalities in a sample of psychoticpatients never exposed to antipsychotic drugs. METHOD: One hundred psychoticpatients were assessed (from January 1998 to December 2002) using DSM-IV criteria for parkinsonism, dyskinesia, akathisia, catatonia, and dystonia at baseline and after 4 weeks of treatment with haloperidol (n = 23), risperidone (n = 52), or olanzapine (n = 25). We examined change scores in neuromotor ratings over the treatment period across treatment groups and rates of drug-responsive and drug-emergent neuromotor syndromes in patients with and without preexisting neuromotor abnormalities. RESULTS: Overall time effects revealed a worsening of parkinsonism (P = .002) and akathisia (P = .002) ratings and an improvement of dyskinesia (P = .001) and catatonia (P < .001) ratings. Main treatment effects revealed that patients taking haloperidol had a significant mean increase in akathisia scores compared with those of patients taking risperidone (P = .002) or olanzapine (P < .001). A significantly greater percentage of olanzapine-treated patients experienced remission of preexisting parkinsonism than did the other treatment groups (P = .047). Patients without preexisting motor abnormalities were more likely to experience drug-emergent parkinsonism if they were treated with haloperidol or risperidone than with olanzapine (P = .001) and were more likely to experience drug-emergent dystonia (P = .014) and akathisia (P = .013) if they were treated with haloperidol than with risperidone or olanzapine. CONCLUSIONS: The relationship between antipsychotic medication and neurologic abnormalities is more complex than previously acknowledged since antipsychotic drugs may both improve preexisting abnormalities and cause "de novo" neurologic syndromes. Overall, olanzapine has a more favorable neuromotor profile than risperidone, which in turn has a more favorable profile than haloperidol.
Authors: Del D Miller; Stanley N Caroff; Sonia M Davis; Robert A Rosenheck; Joseph P McEvoy; Bruce L Saltz; Silvana Riggio; Miranda H Chakos; Marvin S Swartz; Richard S E Keefe; T Scott Stroup; Jeffrey A Lieberman Journal: Br J Psychiatry Date: 2008-10 Impact factor: 9.319
Authors: Jeffrey A Lieberman; Michael Phillips; Hongbin Gu; Scott Stroup; Peiyan Zhang; Lan Kong; Zhongfu Ji; Gary Koch; Robert M Hamer Journal: Neuropsychopharmacology Date: 2003-03-26 Impact factor: 7.853
Authors: Gerard W K Hugenholtz; Eibert R Heerdink; Joost J Stolker; Welmoed E E Meijer; Antoine C G Egberts; Willem A Nolen Journal: J Clin Psychiatry Date: 2006-06 Impact factor: 4.384
Authors: Victor Peralta; Virginia Basterra; Maria S Campos; Elena García de Jalón; Lucía Moreno-Izco; Manuel J Cuesta Journal: Eur Arch Psychiatry Clin Neurosci Date: 2011-05-28 Impact factor: 5.270
Authors: Xiaoming Du; Fow-Sen Choa; Joshua Chiappelli; Krista M Wisner; George Wittenberg; Bhim Adhikari; Heather Bruce; Laura M Rowland; Peter Kochunov; L Elliot Hong Journal: Biol Psychiatry Date: 2018-06-21 Impact factor: 13.382
Authors: Harald Murck; Thomas Laughren; Femke Lamers; Rosalind Picard; Sebastian Walther; Donald Goff; Stephen Sainati Journal: Innov Clin Neurosci Date: 2015 Mar-Apr
Authors: Sebastian Walther; Katharina Stegmayer; Andrea Federspiel; Stephan Bohlhalter; Roland Wiest; Petra V Viher Journal: Schizophr Bull Date: 2017-09-01 Impact factor: 9.306
Authors: Manuel J Cuesta; Ana M Sánchez-Torres; Elena García de Jalón; Maria S Campos; Berta Ibáñez; Lucía Moreno-Izco; Víctor Peralta Journal: Schizophr Bull Date: 2013-09-26 Impact factor: 9.306
Authors: Sebastian Walther; Irena Vladimirova; Danai Alexaki; Lea Schäppi; Kathrine S F Damme; Vijay A Mittal; Stewart A Shankman; Katharina Stegmayer Journal: J Psychiatr Res Date: 2021-11-08 Impact factor: 4.791
Authors: Victor Peralta; Lucía Moreno-Izco; Ana Sanchez-Torres; Elena García de Jalón; Maria S Campos; Manuel J Cuesta Journal: Schizophr Bull Date: 2012-12-18 Impact factor: 9.306